Publikationen, an denen er mitarbeitet Jesús María Hernández Rivas (11)

2023

  1. Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

    Blood, Vol. 141, Núm. 4, pp. 406-421

2022

  1. A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1248-1255

  2. CRISPR/Cas9‐Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML

    International Journal of Molecular Sciences, Vol. 23, Núm. 12

2021

  1. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  2. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia

    CRISPR Journal, Vol. 4, Núm. 4, pp. 519-535

  3. Characterization of the platelet phenotype caused by a germline RUNX1 Variant in a CRISPR/Cas9-generated murine model

    Thrombosis and Haemostasis, Vol. 121, Núm. 9, pp. 1193-1205

2020

  1. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  2. ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia

    Cells, Vol. 9, Núm. 1

2019

  1. Splice donor site sgRNAs enhance CRISPR/ Cas9-mediated knockout efficiency

    PLoS ONE, Vol. 14, Núm. 5

2018

  1. Targeted genome editing in acute lymphoblastic leukemia: A review

    BMC Biotechnology, Vol. 18, Núm. 1

2017

  1. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia

    Oncotarget, Vol. 8, Núm. 16, pp. 26027-26040